152 related articles for article (PubMed ID: 18049337)
1. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Szmania S; Gnjatic S; Tricot G; Stone K; Zhan F; Moreno A; Thuro B; Melenhorst J; Barrett J; Shaughnessy J; Old LJ; Barlogie B; Brichard VG; van Rhee F
J Immunother; 2007; 30(8):847-54. PubMed ID: 18049337
[TBL] [Abstract][Full Text] [Related]
2. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
3. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
[TBL] [Abstract][Full Text] [Related]
5. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
6. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
[TBL] [Abstract][Full Text] [Related]
7. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
9. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
10. MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.
Batchu RB; Gruzdyn O; Potti RB; Weaver DW; Gruber SA
JAMA Surg; 2014 May; 149(5):451-7. PubMed ID: 24671426
[TBL] [Abstract][Full Text] [Related]
11. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
13. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
[TBL] [Abstract][Full Text] [Related]
16. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
[TBL] [Abstract][Full Text] [Related]
18. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
19. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
20. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
